Liminatus Pharma Reports Increased Losses and Improved Liquidity in Latest 10-Q Filing

Liminatus Pharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $1.12 million, a substantial increase from the $327,526 loss reported in the same period last year, reflecting a 243% rise in losses. Total operating expenses surged to $1.1 million, up 317% from $264,220 in the prior year, primarily driven by increased general and administrative costs associated with operating as a publicly traded entity and new research and development expenses related to its CD47 license agreement.

The company’s financial position showed marked improvement in liquidity, with cash reserves increasing to $1.91 million as of March 31, 2026, compared to $337,655 at the end of 2025. This increase was bolstered by a successful public offering completed on February 18, 2026, which raised approximately $3.44 million in net proceeds. The offering included 8,270,000 shares of common stock and various warrants, reflecting a strategic move to enhance capital for ongoing operations and development efforts.

In terms of operational metrics, Liminatus Pharma's total assets rose significantly to $2.79 million from $512,795 at the end of 2025, largely due to the influx of cash from the public offering and the conversion of related party debts into equity. The company’s stockholder deficit decreased to $132,596 from $9.81 million, indicating a positive shift in its equity position following the business combination and subsequent financing activities. The total number of shares outstanding increased to 44,877,633, reflecting the issuance of new shares during the public offering and other transactions.

Strategically, Liminatus Pharma is focused on advancing its lead product candidate, IBA101, a humanized anti-CD47 monoclonal antibody aimed at treating advanced solid tumors. The company is currently in the pre-clinical stage and is preparing for Phase 1 clinical trials. However, the filing also highlighted ongoing challenges, including substantial doubt about the company's ability to continue as a going concern without additional financing. Management is actively seeking further capital through equity and debt financing to support its operations and development plans.

Looking ahead, Liminatus Pharma is working to regain compliance with Nasdaq listing requirements after receiving notices regarding its market value and bid price. The company has until mid-2026 to address these issues. Management remains optimistic about its strategic direction and the potential for its product pipeline, but acknowledges the need for continued financial support to achieve its objectives.